Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a Healthcare company (Biotechnology) with a market capitalization of $60M. The Maz Rating grades it against the other companies in its sector.
Cognition Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.63, Cognition Therapeutics, Inc. trades at 2.0x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -50.6%, return on invested capital of -126.3% and a free cash flow yield of -25.5%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 6.68. Over the past 52 weeks the share price ranged from $0.55 to $1.81, with a beta of 1.80.
Cognition Therapeutics, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 6 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Cognition Therapeutics, Inc. (CGTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.11% / 30% · (Cash+Inv) / Mkt Cap (36m) 38.6% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.11% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 38.6% / 33% · Receivables / Mkt Cap (36m) 3.14% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.11% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 38.6% / 33.33% · Receivables / Mkt Cap (24m) 3.14% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.46% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 84.0% / 33.33% · Receivables / Avg Assets (4Q) 12.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.26% / 33.33% · (Cash+ST Inv) / Total Assets 88.4% / 33.33% · (Cash+Recv) / Total Assets 95.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Cognition Therapeutics, Inc. (CGTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Cognition Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
Cognition Therapeutics, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.